ITGB1抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using ITGB1 mouse mAb against Hela (1), HepG2 (2), A549 (3), Jurkat(4), L1210 (5) and Cos7 (6) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Hela cells using ITGB1 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human ovarian cancer tissues using ITGB1 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using ITGB1 mouse mAb with DAB staining.    

  
  

**Background of ITGB1 Antibody**

Integrin beta-1 (ITGB1), also known as CD29. is a critical subunit of integrin heterodimeric receptors that mediate cell-extracellular matrix (ECM) and cell-cell interactions. It pairs with various alpha subunits (e.g., α1-α11) to form distinct integrins (e.g., VLA proteins), which play essential roles in cell adhesion, migration, signaling, and tissue homeostasis. ITGB1 is ubiquitously expressed and regulates processes like embryogenesis, immune response, wound healing, and cancer progression by transmitting bidirectional signals between the ECM and intracellular cytoskeleton.

ITGB1 antibodies are vital tools for studying integrin functions. They are used to block ligand binding, modulate signaling (agonistic/antagonistic effects), or detect ITGB1 expression in techniques like flow cytometry, Western blotting, and immunohistochemistry. In research, these antibodies have revealed ITGB1's involvement in tumor invasion, angiogenesis, and resistance to therapy, highlighting its potential as a therapeutic target. For instance, inhibitory ITGB1 antibodies suppress cancer metastasis by disrupting ECM adhesion.

Clinically, ITGB1 dysregulation is linked to fibrosis, autoimmune diseases, and metastatic cancers. While no ITGB1-targeted therapies are yet approved, preclinical studies explore monoclonal antibodies or antibody-drug conjugates to modulate ITGB1 activity. Challenges remain in minimizing off-target effects due to ITGB1's broad tissue distribution. Overall, ITGB1 antibodies remain pivotal in unraveling integrin biology and advancing translational applications.